Pros and cons: in the ATRA and ATO era, do we need maintenance therapy for high-risk acute promyelocytic leukemia? Read the PROS by Martin S. Tallman. haematologica.org/article/view/1…

Read it once and then read it again :-)

This was Black Sabbath's final moment. The last performance. The last song.

Teaching vs Mentoring vs Coaching

In REACH3, ruxolitinib vastly improved failure-free survival (38.4 vs 5.7 months) over best therapy in steroid-refractory chronic GVHD, with durable responses and no new safety issues over 3 years. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

AI will change Haematology !

How cool is this !!!

A very interesting new prospective in DVT

Anemia defines a different subset of MF patients ?

The question is are we ready to replace monotherapy ? And what are the costs implications? What about survival benefit ?

New clinical trials should embrace this concept rather than still aim for spleen reduction

New partnership brings specialist baby loss support to bereaved parents in Lincolnshire: Bereaved parents will benefit from specialist counselling thanks to a hospital charity-funded partnership between United Lincolnshire Teaching Hospitals NHS Trust… dlvr.it/TLylmv

proud of you Prof Alfredo Addeo MD

The Bone Marrow Microenvironment in Myelodysplastic Syndromes—Pathogenesis, Immune Evasion, and Therapeutic Opportunities mdpi.com/si/248235 #mdpicancers via Cancers MDPI

Pleased to announce the launch of this special issue as Guest Editor. Looking forward to great papers submission The Bone Marrow Microenvironment in Myelodysplastic Syndromes—Pathogenesis, Immune Evasion, and Therapeutic Opportunities mdpi.com/si/248235 #mdpicancers via

Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML HemaSphere Journal (IF = 14.6) sohoinsider.com/news/eprenetap…

We're proud to have officially launched the Lincoln Institute for Rural and Coastal Health (LIRCH)—the UK’s first dedicated research institute focused on tackling health inequalities in rural and coastal communities. ✨ Read more: lncn.ac/LIRCH25

Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial targetedonc.com/view/revumenib… via @targetedonc Coming soon as one of our new AML trial in Lincoln

👉Treatment patterns and blood count control in 10,112 patients with polycythemia vera | ⁦Naveen Pemmaraju, MD⁩ et al #MPNSM tandfonline.com/doi/full/10.10…

🚨 A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia - Clinical Lymphoma, Myeloma and Leukemia clinical-lymphoma-myeloma-leukemia.com/article/S2152-… | Hannah Goulart Marina Konopleva Nitin Jain #leusm #endcancer